The Effects of Nocturnal Non-invasive Ventilation in Stable COPD

Noninvasive Ventilation Clinical Trial

— RECAPTURE  

Official title:

Nocturnal Non-Invasive Ventilation in COPD Patients With Stable Hypercapnic Respiratory Failure: Why and in Which Patient Might This be Effective?

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03053973
• Other study ID #: 201700097
• Status: Recruiting
• Phase: N/A
• Start date: November 13, 2017
• Est. completion date: November 1, 2025

Study information

• Verified date: November 2023
• Source: University Medical Center Groningen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Rationale:

Application of long-term non-invasive ventilation (NIV) in chronic obstructive pulmonary disease (COPD) patients with chronic hypercapnic respiratory failure (CHRF) has recently been shown to improve outcomes. However, the mechanism behind these improvements are unknown. We hypothesize that NIV stabilizes FEV1 via beneficial effects on inflammation and repair pathways in patients with COPD. In the present study we aim to investigate, in COPD patients with CHRF,

1. change in FEV1 after 3 months nocturnal NIV in stable hypercapnic COPD patients as compared to standard care

2. the relationship between FEV1 change and modification of systemic and airway inflammation and remodelling, lung hyperinflation, and airway morphology.

3. predictors of a favourable response to chronic NIV in COPD patients with CHRF. Study design: multicentre randomised controlled study investigating the effects of NIV on airway morphology, airway inflammation and remodelling in hypercapnic COPD patients including a control group that will postpone the initiation of NIV for 3 months. In addition we will investigate how patient demographics, patient and disease characteristics and systemic and airway inflammation predict the response to chronic NIV in severe stable COPD. To do this, all patients will be followed for 6 months after NIV initiation.

Main study parameters/endpoints: The main endpoint is the change FEV1 after 3 months. Furthermore, as we recognise that FEV1 might not be the most important patient-related outcome, we will assess which parameters affect health-related quality of life after 3 and 6 months.

Description:

Rationale: Application of long-term non-invasive ventilation (NIV) in chronic obstructive pulmonary disease (COPD) patients with chronic hypercapnic respiratory failure (CHRF) has recently been shown to improve outcomes when applied with sufficiently high inspiratory pressures and adequate backup breathing frequencies (high-intensity NIV). Interestingly, it has been demonstrated that nocturnal NIV improves not only clinical but also physiological parameters like arterial carbon dioxide pressure (PaCO¬2¬) and forced expiratory volume in 1 second (FEV1) in patients with stable COPD. However, the mechanism behind these improvements are unknown. Furthermore, it is unclear whether this improvement in lung function influences health-related quality of life (HRQoL), the utmost goal of chronic NIV in COPD, or that other baseline patient- and ventilatory characteristics are more important in predicting a long-term beneficial effect.

We hypothesize that NIV stabilizes FEV1 via beneficial effects on inflammation and repair pathways in the airways of patients with COPD. We aim to study this hypothesis and to investigate the regulation of lung function, markers of inflammation and repair pathways in airway biopsies, bronchial wash and bronchial and nasal epithelium in response to home mechanical ventilation. The second goal of this study is to define a phenotype of patients with COPD, based on baseline characteristics and biomarkers, such as markers of inflammation, who will respond to NIV therapy with improvements in lung function and HRQoL.

Objectives:

1. To investigate change in FEV1 after 3 months nocturnal NIV in stable hypercapnic COPd patients as compared to standard care

2. To investigate the relationship between FEV1 change and modification of systemic and airway inflammation and remodelling, lung hyperinflation, and airway morphology.

3. To investigate predictors of a favourable response to chronic NIV in COPD patients with CHRF.

Study design: The study is multicentre randomised controlled study investigating the effects of NIV on airway morphology, airway inflammation and remodelling in hypercapnic COPD patients including a control group that will postpone the initiation of NIV for 3 months. To measure these parameters a bronchoscopy with a bronchial wash and bronchial biopsies and high-resolution CT-scanning we be done at baseline and after 3 months. In a addition we will investigate how patient demographics, patient and disease characteristics and systemic and airway inflammation predict the response to chronic NIV in severe stable COPD. To do this, all COPD patients initiated on NIV in our centre will be followed for 6 months after NIV initiation as part of the present study.

Study population: Patients who have an indication for NIV (COPD Global Initiative of Obstructive Lung Disease (GOLD) III or IV and a PaCO2 > 6.0 kilopascal (kPa) in stable disease) in the Netherlands will be asked to participate.

For investigating airway inflammation, to ensure safety during the bronchoscopies, patients with severe gas exchange derangements (i.e. PaCO2 > 8.0 kPa and /or partial arterial oxygen pressure (PaO2)<6.5 kPa at rest during spontaneous breathing), and instable cardiac comorbidities will be excluded. These patients will be included to be followed for 6 months prospectively after NIV initiation, according to the same protocol, however, without CT-scanning and bronchoscopies.

Main study parameters/endpoints: The main endpoint is the change FEV1 after 3 months. Several markers of blood and airway inflammation and remodeling will be assessed to analyse mechanisms of FEV1 improvements.

Furthermore, as we recognise that FEV1 might not be the most important patient-related outcome, we will assess which parameters affect health-related quality of life after 3 and 6 months. For this, parameters of the total group of patients will be used.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 116
• Est. completion date: November 1, 2025
• Est. primary completion date: August 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Indication to initiate chronic NIV in COPD patients (GOLD stage III or IV: FEV1/ forced expiratory volume (FVC)< 70% and FEV1< 50% predicted; PaCO2 > 6.0 kilopascal (kPa) in stable condition, which means no COPD exacerbation for 4 weeks and a pH > 7.35)

• Age > 18 years

• Written informed consent is obtained

Exclusion Criteria:

For the randomised Inflammation part a potential subject who meets any of the following criteria will be excluded from participation in this study:

• Oral corticosteroids or roflumilast

• A history of lung volume reduction surgery

• Body mass index (BMI) > 35 kg/m2

• Obstructive sleep apnoea (OSA) (apnoea/hypopnea index (AHI) >15/hr): to exclude OSA a polygraphy will be done at baseline

• PaCO2 = 8.0 kPa or PaO2 < 6.5 kPa at rest without oxygen

• Instable cardiac comorbidities (left ventricular ejection fraction (LVEF) <40%, instable coronary artery disease, instable heart failure)

Related Conditions & MeSH terms

• Noninvasive Ventilation

Intervention

Device:
• nocturnal noninvasive ventilation
Patients will be initiated on bilevel positive pressure non-invasive ventilation via a mask according to regular clinical practice.

Other:
• Standard Care
Standard COPD care is given to all patients (pharmacological management, oxygen, rehabilitation if neccesary, etc.)

Locations

Country	Name	City	State
Netherlands	University Medical Center Groningen	Groningen

Sponsors (1)

Lead Sponsor	Collaborator
Peter Wijkstra

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	FEV1	Change in Forced expiratory volume in one second	baseline, 3 months
Primary	Health-Related Quality of Life	Change in HRQoL assessed by the severe respiratory insufficiency questionnaire summary score (SRI)	baseline, 3 months, 6 months
Secondary	Safety: the number of adverse events will be recorded.	The number of adverse events will be recorded.	baseline, 3 months, and 6 months
Secondary	Health-related quality of life assessed with the SF-36	Additional assessment of generic and disease specific aspects of HRQoL, evaluated with the SF-36.	baseline, 3 months, 6 months
Secondary	Anxiety and depression	Anxiety and depression, evaluated by the hospital anxiety and depression scale (HADS).	baseline, 3 months, 6 months
Secondary	Activities and Restrictions,	Activities and Restrictions, assessed with the Groningen Activity and Restriction Scale (GARS).	baseline, 3 months, 6 months
Secondary	Caregiver Burden	Caregiver Burden, assessed with the Caregiver Strain Index (CSI)	baseline, 3 months, 6 months
Secondary	Dyspnoea	Dyspnoea, using the Medical Research Council (MRC) score.	baseline, 3 months, 6 months
Secondary	Gas exchange day	Gas exchange at daytime without additional oxygen assessed with an arterial blood gas analysis	baseline, 3 months, 6 months
Secondary	Gas exchange night	Gas exchange during the night assessed with transcutaneous CO2 measurements.	baseline, 3 months, 6 months
Secondary	Respiratory muscle activity	Respiratory muscle activity during the night and during NIV will be assessed with surface electromyography (EMG)	baseline, 3 months
Secondary	Spirometry	Spirometry will be used to assess forced expiratory volumes	baseline, 3 months, 6 months
Secondary	Exercise tolerance	Exercise tolerance assessed by the 6-minute walking distance.	baseline, 3 months, 6 months
Secondary	Peripheral muscle function	The 1-repetition maximum strength test will performed using a resistance weight-lifting machine	baseline, 3 months
Secondary	Compliance with the ventilator	Compliance will be read from the ventilator counter readings	baseline, 3 months, 6 months
Secondary	Venous blood	Venous samples will be obtained for analyses of inflammatory markers	Baseline, 3 months
Secondary	Urine albumin to Creatinine ratio	Urine portion for albumin and creatinine will be obtained to obtain the albumin to creatinine ratio	Baseline, 3 months
Secondary	Nasal epithelium markers of remodelling and repair	For detailed description see the airway brush markers.	Baseline, 3 months
Secondary	Airway abnormalities	Airway abnormalities will be assessed with a High Resolution computertomography (HRCT) scanning with in- and expiration.	Baseline, 3 months
Secondary	Airway inflammation and remodeling	Airway inflammation and remodeling assessed with bronchial brushes and washes and airway biopsies obtained through bronchoscopy. Several markers leading to one profile will be assessed	Baseline, 3 months
Secondary	HRQoL assessed with CCQ	Additional assessment of generic and disease specific aspects of HRQoL, evaluated with the Clinical COPD Questionnaire (CCQ).	Baseline, 3 months, 6 months
Secondary	Patient-ventilator asynchrony	Patient-ventilator asynchrony during the night and during NIV will be assessed by comparing surface electromyography (EMG) signals with ventilator pressure tracings	baseline, 3 months
Secondary	Lung volumes	Bodyplethysmography will be used to assess lung volumes	baseline, 3 months, 6 months
Secondary	Emphysema	The amount of emphysema and air-trapping assessed with a High Resolution computertomography (HRCT) scanning with in- and expiration, and captured into an emphysema score.	baseline, 3 months